Riverine Ventures

CellFE Inc. is a San Carlos, California-based company that specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. Founded in 2017, CellFE's innovative platform employs rapid cell compressions to enhance the uptake of therapeutic molecules from the surrounding fluid, facilitating the development and manufacturing of advanced cell therapies. This technology aims to address previously inaccessible cell therapies, enabling medical researchers to transport difficult-to-deliver molecules into cells for the treatment of various disorders, ultimately improving patient outcomes.

Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.